Lipoxygenase inhibiting compounds
US5175183A · kind A · utility
27Cited by
10References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 10, 1991 |
| Grant date | Dec 29, 1992 |
| Priority date | — |
| Expiry date | Jul 10, 2011 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2601/02
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Certain N-aryl, N-heteroaryl-, N-arylalkyl-, N-heteroarylalkyl-, N-arylcyclopropyl- and N-heteroaryl-cyclopropyl-N'-hydroxyurea compounds are inhibitors of lipoxygenase enzyme activity and are thus useful agents in treating disease states such as asthma, arthritis, allergy, psoriasis, inflammatory bowel disease, gout, adult respiratory distress syndrome, endotoxin shock, and other inflammatory conditions in which the products of the arachidonic acid cascade are implicated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.